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Abstract 
We have recently shown that human recombinant BMP-6 (rhBMP-6), given 
systematically, can restore bone in animal models of osteoporosis. To further elucidate 
the underlying mechanisms of new bone formation following systemic application of 
BMPs we conducted gene expression profiling experiments using bone samples of 
ovariectomized mice treated with BMP-6. Gene Set Enrichment Analysis revealed 
enrichment of insulin-like growth factor-I and epidermal growth factor related pathways 
in animals treated with BMP-6.  Significant upregulation of IGF-I and EGF expression in 
bones of BMP-6 treated mice was confirmed by quantitative PCR. To develop an in vitro 
model for evaluation of the effects of BMP-6 on cells of human origin, we cultured 
primary human osteoblasts. Treatment with rhBMP-6 accelerated cell differentiation as 
indicated by the formation of mineralized nodules by day 18 of culture versus 28 to 30 
days in vehicle treated cultures. In addition, alkaline phosphatase gene expression and 
activity were dramatically increased upon BMP-6 treatment.  IGF-I and EGF expression 
was upregulated in human osteoblast cells treated with BMP-6. These results collectively 
indicate that BMP-6 exerts its osteoinductive effect at least in part through IGF-I and 
EGF pathways, which can be observed both in a murine model of osteopenia and in 
human osteoblasts.   
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Introduction 
Bone morphogenetic proteins (BMP) are potent local factors that have been shown to 
have specific functions during organogenesis and embryogenesis, regulate the 
differentiation of mesenchymal progenitor cells and promote bone and cartilage 
formation in bone and cartilage defects, fracture repair and periodontal diseases (3, 5, 11, 
15-17). BMPs are members of the transforming growth factor-β (TGF-β) superfamily and 
were first identified by their ability to induce ectopic bone formation in vivo (11).  
The function of individual BMPs have been evaluated in vitro using various cell lines, 
e.g., multipotent progenitor cells, osteoprogenitor cells, osteoblasts, chondroblasts, and 
osteosarcoma cells (22). BMPs were shown to be important in osteoblast differentiation 
(23, 24) and  bone formation in vivo, where they, in concert with other cytokines and 
matrix components, induce sequential cascade events for chondro-osteogenesis, 
consisting of chemotaxis, mesenchymal proliferation and differentiation, angiogenesis, 
and controlled synthesis of extracellular matrix (11, 18, 24) 
Recently, we have shown that human recombinant BMP-6 (rhBMP-6), administered 
systematically, induces new bone formation in both osteoporotic rats and mice (19, 20). 
In order to elucidate the underlying mechanism of new bone formation following 
systemic application of BMP-6 we conducted gene expression profiling in bone tissue of 
ovariectomized (OVX) mice following BMP-6 therapy.  Primary human osteoblasts 
served as an in vitro model for evaluation of the in vivo effect of BMP-6 human bone-
derived cells.  
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Materials and Methods 
Animals  
Wild type C57BL/6J mice were purchased from Charles River, Budapest, Hungary. 
Animals were maintained in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals (14). All protocols were approved by Institutional Ethics Committee 
and Ministry of Science Grant Review Committee. At three months of age in sham mice 
ovaries were exteriorized but replaced intact, while bilateral OVX with dorsal approach 
was performed in the remaining mice. Animals were left untreated for three weeks 
following surgery to await the development of osteopenia and then divided into the 
following groups: (1) sham (n=10), (2) OVX (n=10), (3) OVX + BMP-6 (10 µg/kg 
intravenously, 3 times x week) (n=10). Human mature BMP-6 was produced in CHO 
cells and purified as previously described (6, 20). Therapy started 3 weeks following 
OVX and continued for the next nine weeks for bone densitometry measurements (n=15) 
or four weeks for gene expression analysis (n=15) when the animals were euthanized by 
cervical dislocation.   
Bone mineral density (BMD) measurements  
To determine the anabolic effect of BMP-6 on bone tissue, ex vivo BMD measurements 
of lumbar spine, femurs and tibiae were performed by a PIXImus apparatus (Norland, 
Medizintechnik, Pforzheim, Germany) according to manufacturer's instructions (using the 
mouse-specific software - version 1.43).  
Cell Culture   
Normal human osteoblasts were purchased from Cambrex Bioscience (Cambrex, 
Walkersville, MD, USA). Cells were plated in 12-well dishes at a density of 5000 
cell/cm2 in Osteoblast Basal Growth Medium (OBGM) containing 10% Fetal Bovine 
Serum, ascorbic acid (100 µg/ml) and antibiotics.  Media were replaced every two days 
until cells were confluent and then media were replaced every two days until the 
completion of experiment with Differentiation Media (OBGM additionally supplemented 
with 1 µM dexamethasone and 10 mM β-glycerolphosphate). BMP-6 was added at 
plating and at every feeding in concentration of 100 ng/ml. 
Cell number,  alkaline phosphatase activity and in vitro mineralization 
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Cells were plated and cultured ± BMP-6 and at subsequent time points (1, 2, 3, 6, 10, 18, 
28 and 37 days) were trypsinized, collected, rinsed with PBS and counted on a 
hemacytometer.  Alkaline phosphatase activity was measured over a 28 day period at 
specific time points (6, 10, 14, 19, 23 and 28 days) as previously described (22) and 
expressed as product produced/min/µg protein. Adherent cell cultures from day 19 
through day 28 were stained for the presence of mineral using the method of Von Kossa 
as previously described (4). Mineralized nodules appeared dark brown and were 
photographed using a Spot digital camera (Diagnostic Instruments, Inc., Sterling Heights, 
MN, USA). 
RNA isolation and reverse transcription  
Total RNA was isolated from the whole murine femur samples using both TRIzol reagent 
(Invitrogen, Carlsbad, CA, USA) and RNeasy Mini Kit (Qiagen, Hilden, Germany) and 
from the primary human osteoblasts using only RNeasy Mini Kit. The quality of RNA was 
analyzed on a 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). One-Step 
quantitative RT-PCR was performed on 2.5µg (bone samples) or 1 µg (cell culture) of total 
RNA using Superscript First-Strand Synthesis System (Invitrogen, Carlsbad, CA, USA).   
Μicroarray and Gene Set Enrichment Analysis 
Μicroarray analysis was performed using Mouse Genome 430 2.0 GeneChips (Affymetrix, 
Santa Clara, CA, USA), which contains 45 000 25-mer probe sets. The RNA from murine 
samples was processed using the standard Affymetrix protocol. Usual quality measures and 
normalization for the Affymetrix GeneChip were used in the experiments. All arrays were 
run in the same core facility at the Center for Functional Genomics, School of Medicine, 
University of Zagreb. 
In an effort to test the functional correlation of gene sets that might be systemically 
altered in mice treated with BMP-6, we applied a statistical method called Gene Set 
Enrichment Analysis (21). Using gene expression profiles of OVX mice treated with 
BMP-6 we calculated the enrichment scores (ES) of 472 predefined gene sets (MSigDB1, 
Broad Institute, Boston, USA) containing genes involved in specific metabolic and 
signaling pathways and 50 sets containing genes coregulated in response to genetic and 
chemical stimuli. Estimated statistical significance (nominal P value) of the ES was also 
calculated by using an empirical phenotype-based permutation test procedure that 
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preserves the complex correlation structure of the gene expression data. Nominal P value 
of P<0.05 was taken as a cut-off value in the analysis. 
Gene expression analysis by quantitative PCR  
For experiments performed on murine samples, gene expression of interest was measured 
using LightCycler FastStart DNA Master SYBR Green kit (Roche Diagnostics, 
Mannheim, Germany) in the LightCycler instrument (Roche Diagnostics, Mannheim, 
Germany). The comparative CT method (∆∆CT) was used for relative quantification of 
gene expression (10). Expression of four housekeeping genes was analyzed and 
glyceraldehyde-3-phosphate dehydrogenase was chosen as the most stable housekeeping 
gene. Results are represented as fold change of comparative expression level to OVX 
group of animals. Sequence of primers is shown in  Table 1.  
Total RNA from human osteoblast cultures, isolated at various time points (1, 2, 6, 10, 
14, 18, 23, 28 days), was analyzed using different q-PCR method to compensate for 
lower RNA yield and accordingly weaker gene expression. Human primer/probe sets 
(assay numbers available on demand) were purchased as a 20X assay-on-demand mix 
from Applied Biosystems (Foster City, CA, USA). Data were normalized to the 
expression of Acidic Ribosomal Binding Protein which showed no change in mRNA 
expression with BMP-6 treatment. 
Statistical analysis  
Densitometric data measurement and changes in gene expression in mice were analyzed 
with One way ANOVA with one-sided Dunett-t post hoc test against OVX animals test 
(p<0.05). Changes in gene expression in the cell culture were analyzed with Student T-
test (p<0.05). 
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Results 
BMP-6 induces new bone formation in OVX mice and enhances differentiation of 
human osteoblasts 
Bone mineral density (BMD) measurements showed that systemic administration of BMP-
6 for a period of nine weeks restored bone volume of both the peripheral and the axial 
skeleton of OVX mice. BMD values of tibiae, femurs and vertebrae were increased for 
12.8%, 10% and 7.4%, respectively, in mice treated with BMP-6 (Figure 1).  
To develop an in vitro model for evaluation of the effect of BMP-6 on the cells of human 
origin, we used the primary human osteoblasts (HOB). After intensive proliferation 
period (first ten days of culture), cell number remained relatively stable between day 10 
and day 28 of culture. No statistically significant difference was seen between BMP-6 
and untreated cultures indicating that BMP-6 does not effect the cell growth (Figure 2a).  
In order to determine the effect of BMP-6 treatment on the differentiation of HOBs, 
alkaline phosphatase activity was measured, and increased from day 14 to day 23 by 2-
2.7 fold in BMP-6 treated cultures when compared to untreated cells (Figure 2b). Since 
numerous osteoblastic cell lines spontaneously form mineralized nodules during the 
process of cell differentiation and matrix mineralization, we tested whether BMP-6 
enhances the nodule formation in the primary human osteoblasts. We found that 
following BMP-6 treatment the cells formed mineralized nodules between day 18 and 23 
of culture (Figure 2c).  Cell cultures not exposed to BMP-6 did not show the formation of 
mineralized nodules until day 30 of culture (data not shown). 
Effect of BMP-6 on markers of osteogenic activity 
Gene expression analysis of common markers of osteogenic activity (AP, osteocalcin, 
collagen I and BMPs) confirmed that BMP-6 induces osteoblast differentiation both in 
vivo and in vitro. In mice, 4 weeks of BMP-6 therapy induced expression of AP above the 
sham value (Figure 3a). No change in alkaline phosphatase gene expression was observed 
when the comparison was made between BMP-6 treated cultures and untreated cultures 
until approximately day 19 of culture where the difference was 3.2-fold higher in the 
BMP-6 treated cultures as compared to control cultures.  By day 23 of culture, the 
difference in alkaline phosphatase mRNA levels had risen to 4.3-fold and to 6-fold by 
day 28 of culture (Figure 3f).   
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In mice osteocalcin and collagen type I expression was increased upon BMP-6 treatment 
(Figure 3b and c). On the contrary expression of these common markers of differentiated 
osteoblasts showed no difference in the expression levels when untreated and BMP-6 
treated cultures were compared (Figure 3g and h). In mice, BMP-6 expression was not 
changed following OVX, but was reduced 4 weeks after BMP-6 therapy (Figure 3d). 
Endogenous BMP-6 expression increased upon differentiation of HOBs, and addition of 
exogenous BMP-6 resulted in a decrease of BMP-6 transcripts expression (Figure 3i) 
indicating the ability of BMP-6 to auto-regulate its own expression level. Expression of 
BMP-4 was reduced in OVX animals and significantly increased after BMP-6 therapy 
(Figure 3e). On the contrary, in HOBs no change in the expression of BMP-4 was 
observed in either treated or untreated cells during the period of 30 days (Figure 3j). We 
observed no change in the BMP-2 expression in OVX and BMP-6 treated mice (data not 
shown). Similarly, in HOBs there was an analogous pattern of increased BMP-2 
expression with BMP-6 treatment as compared to control cultures (Figure 3j). 
Activation of IGF-I and EGF pathways upon BMP-6 treatment 
To elucidate the underlying mechanisms of the new bone formation following systemic 
application of BMP-6 we analyzed the gene expression profile in OVX mice receiving 
BMP-6. In order to ascertain whether BMP-6 can activate formation related pathways in 
OVX animals, we performed BMP-6>OVX analysis using GSEA (Table 2). BMP-6 
treatment specifically enriched IGF-I related pathways, including IGF-I MTOR pathway 
and insulin signaling. Epidermal growth factor (EGF) pathway was also highly enriched, 
indicating that BMP-6 might at least in part achieve its effects through the activation of 
IGF-I and EGF. OVX>BMP-6 comparison revealed increased enrichment of interleukin-
1 receptor pathway, which indicates that BMP-6 treatment reduced the cytokine 
production in OVX animals. This could also be substantiated by an increased enrichment 
of cell adhesion molecule activity pathway in OVX, which includes known effectors of 
immune response, such as intercellular adhesion molecule 1. WNT signaling was also 
highly enriched, specifically the WNT beta catenin and WNT signaling pathways. 
Effect of BMP-6 on expression of IGF-I and EGF was subsequently determined by 
quantitative PCR. Analysis of the gene expression in murine bones confirmed the results 
obtained by microarray. It was shown that IGF-I, IGF-II binding protein 3 and EGF 
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expression was reduced following OVX (Figure 4 a-c) and that BMP-6 therapy corrected 
altered gene expression levels. In human osteoblasts it was confirmed that BMP-6 
induces expression of both EGF and IGF-I. The peak of the IGF-I expression was 
observed in the beginning of the treatment (day 7), followed by decline, but the 
expression was still elevated compared to vehicle cultures. Expression of EGF was also 
increased upon BMP-6 treatment, and again on day 12 and 23 of the culture period 
(Figure 4 d and e). 
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Discussion 
In this study we explored the mechanisms by which BMP-6 induces new bone formation 
in OVX mice and effects the differentiation of human osteoblasts. It was shown that 
BMP-6 induced enrichment of IGF-1 and EGF related pathways in both experimental 
models.  
The activities of bone formation and resorption are regulated by systemic hormones and 
local factors produced in bone (2). IGFs are among the most important regulators of bone 
cell function because of their abundance and their proven anabolic effects on the skeleton 
(1, 12, 13). IGF-I regulates bone formation and remodeling by induction of early 
osteoblast gene expression in the differentiation of mature osteoblastic and 
preosteoblastic cells (8). It was shown that BMP-7 can act locally by modulating the IGF 
regulatory system, suggesting that the mitogenic/differentiative effect of BMP-7 on 
human bone cells may in part be mediated via IGF-II (7). Activation of IGF-I and 
markers of early osteoblastic differentiation by BMP-6 in both mice and cell cultures of 
human osteoblasts indicates that BMP-6 might act on bone at least partially via the IGF-I-
related pathways and that this mechanisms might be regulated by mutual interactions.  
In addition, BMP-6 upregulation of EGF in bones and osteoblasts has not been previously 
demonstrated and serves as an additional collaboration pathway for transmitting its 
anabolic bone effect. Recently, importance of EGF and EGF-like ligands in regulating 
bone growth and modeling has been discovered (25), including the fact that EGF 
stimulates the differentiation of human mesenchymal stem cells into bone-forming cells 
as a single molecule picked by a full scale proteomic analysis (9). This finding might 
explain how BMP-6 forms bone in the bone marrow of OVX mice lacking Bmp-6 gene 
(19). Thus, EGF might contribute to the BMP-6 anabolic effect on bone in vivo, which 
has been confirmed in this study also on human osteoblasts.  
These results collectively indicate that BMP-6 exerts its osteoinductive effect at least in 
part through the IGF-1 and EGF pathways, which was observed both in a murine model 
of osteopenia and in human osteoblastic cell line and could serve as a basis for 
developing new bone-forming drugs based on BMP-6 biology.  
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Figure legends 
Figure 1.  Ex vivo BMD values of sham, OVX and BMP-6 treated mice as analyzed by 
PIXImus. Within 9 weeks of therapy BMP-6 restored bone volume of tibiae (a), femurs 
(b) and lumbar spine (c). *, significantly different from OVX control mice (p<0.05,  
ANOVA, Dunnett test).  
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Figure 2.  Primary human osteoblasts upon BMP-6 treatment. a) Cell number during the 
culture period. BMP-6 did not significantly affect cell growth when compared with 
untreated cultures. b) An increase in alkaline phosphatase activity is seen beginning at 
day 10 of culture in BMP-6 treated cultures.  This activity appeared to peak at day 23 of 
culture. *, significantly different from untreated cell cultures (p<0.05,  Student T-test) .c) 
In vitro human osteoblast cultures were Von Kossa stained. High magnification views 
represent BMP-6 treated human osteoblasts  at days 19, 23 and 28 days of culture. Areas 
of mineralization appear brown. Mineralization usually appeared at approximately day 19 
of culture.  
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Figure 3.  Gene expression of osteogenic markers in mice and human primary osteoblast treated by BMP-6. Total RNA was isolated 
from femurs of mice (n=15) (a-e) following 4 weeks of BMP-6 therapy and from human osteoblasts at certain time points (day 2,6, 10, 
14, 19, 23 and 28) of culture (f-j). Results are represented as fold change of comparative expression level to OVX group of animals  
(a-e) or as fold change as compared to the first day of culture period (f-j). *, significantly different from OVX control mice (p<0.05,  
ANOVA, Dunnett test). 
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Figure 4. Gene expression of IGF-I (a), EGF (b) and IGFbp3 (c) in mice and IGF-I (d) and EGF (e) in human primary osteoblast 
treated with BMP-6. Total RNA was isolated from femurs of mice (n=15) (a-c) following 4 weeks of BMP-6 therapy and from human 
osteoblasts at certain culturing time points (day 7, 12, 17, 23) (d, e) Results are represented as fold change of comparative expression 
level to OVX group of animals  (a-c) or as fold change as compared to the first day of culture period (d, e). *, significantly different 
from OVX control mice (p<0.05,  ANOVA, Dunnett test). 
 18 
Table 1. List of primers used in quantitative PCR reactions for gene expression analysis 
in murine femurs 
Gene  Forward Primer Reverse primer 
AP 5'-CGGACATCATGAGGGTAAGG-3' 5'-GAG ACA TTT TCC CGT TCACC-3' 
BMP 4 5'-GACTTCGAGGCGACACTTCTA-3' 5'-GCCGGTAAAGATCCCTCATGTAA-3' 
BMP 6 5'-CAACGCCCTGTCCAATGAC-3' 5'-ACTCTTGCGGTTCAAGGAGTG-3' 
EEF1 5'-ACCGCACCCCTGAATTTCTC-3' 5'-CTGGCGTACTTCCTCGCAG-3' 
EGF 5'-TTGGTATGCAAGGATGTGTC-3' 5'-CCACTTTGCGAAGTAACTTGGTA-3' 
GAPDH 5'-AGGTCGGTGTGAACGGATTTG-3' 5'-TGTAGACCATGTAGTTGAGGTCA-3' 
IGF2bp3 5'-GTTGAGCACTCGGTCCCTAAA-3' 5'-CCGTTTCCGAATCCGTGTT-3' 
IGF-I 5'-GACCGAGGGGCTTTTACTTCA-3' 5'-GGACGGGGACTTCTGAGTCTT-3' 
Osteocalcin 5'-CTGACCTCACAGATCCCAAGC-3' 5'-TGGTCTGATAGCTCGTCACAAG-3' 
Collagen type I 5'-TGTGTGCGATGACGTGCAAT-3' 5'-GGGTCCCTCGACTCCTACA-3' 
β-2-microglobulin 5'-TTCTGGTGCTTGTCTCACTGA-3' 5'-CAGTATGTTCGGCTTCCCATTC-3' 
β-actin 5'-GTGGGCCGCTCTAGGCACCAA-3' 5'-CTCTTTGATGTCACGCACGATTTC-3' 
  
Abbreviations used in the table: AP = Alkaline phosphatase; BMP = Bone morphogenetic 
protein; EE1G = Eukaryotic translation elongation factor 1 gamma; GAPDH = 
Glyceraldehyde-3-phosphate dehydrogenase; IGF = Insulin growth factor; bp = binding 
protein 
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Table 2.  Functional sets of genes specifically altered in BMP-6 treated mice 
 
Pathway name ES 
Wnt_Signaling 0,348 
il1rPathway 0,330 
ST_Wnt_beta_catenin_Pathway 0,322 
p38mapkPathway 0,310 
cell_adhesion 0,306 
lairPathway 0,300 O
V
X
 
 
v
s.
 
B
M
P-
6 
FRASOR_ER_UP 0,239 
carm-erPathway 0,399 
igf1mtorPathway 0,239 
etsPathway 0,216 
egfPathway 0,170 
BM
P-
6 
v
s.
 
O
V
X
 
igf1rPathway 0,147 
 
GSEA results of functional sets of genes altered following BMP-6 therapy. n=5 per 
group. ES=enrichment score. Estimated statistical significance of p<0.05 was taken as a 
cut-off value in the analysis. 
 
